Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer

Adjuvant Gemcitabine/Capecitabine: New Standard of Care for Resected Pancreatic Cancer


Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.

A roundup of FDA oncology news from September 2013


The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.

First generic version of Xeloda FDA approved

First generic version of Xeloda FDA approved

A generic version of the oral chemotherapy drug Xeloda (capecitabine) has been approved by the U.S. Food and Drug Administration to treat cancers of the colon/rectum or breast.

Eribulin has greater overall survival benefit than capecitabine for metastatic breast cancer


In women with previously treated metastatic breast cancer who shared certain traits, treatment with the newer chemotherapy agent eribulin mesylate had increased benefit over capecitabine.

Eribulin may be useful earlier in breast cancer

A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.

Combination therapy in metastatic CRC

Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown.

Cancer drug causes loss of fingerprints

A cancer patient was detained for four hours by immigration officials in the US because one of his cancer drugs had caused his fingerprints to disappear.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs